Andrew S. Wasmuth

Suggest Changes
Learn More
PURPOSE To evaluate the pharmacologic activity of a novel inhibitor of IκB kinase β (IKK2), LY2409881, in preclinical models of B- and T-cell lymphoma, as a single agent and in combination with(More)
  • 1